Kbp Biosciences Co., Ltd.

Xuanzhu Pharma Co., Ltd.

Shanton Pharma Co., Ltd

Kbp Biosciences Pte. Ltd.

Sihuan Pharmaceutical Holdings Group Ltd.

Shanton Pharma Pte. Ltd.

Zhenhua Huang

Yanyan Dong

Jinyuan Wang

Dedong Zhang

Qian Zhang

Chen Jiang

Yan Zhang

Min Zhang

Li Li

Guanglian Zhou

Jinrong Liu

Mei Hong

Yuntao Song

Shuangshuang Chi

Xiaocui Guo

Provided are a pharmaceutical composition comprising a mineralocorticoid receptor antagonist and use thereof. When the pharmaceutical composition is orally administered to a patient having chronic kidney disease in need thereof, the effective and safe AUC ranges from 188 ng*h/mL to 3173 ng*h/mL, with bioavailability of 50% or more in mammals. When the pharmaceutical composition is orally administered at a daily dose of 0.1 to 1.0 mg to treat chronic kidney disease, the AUC is controlled at a safe and effective level.

Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof

The present invention provides a novel antibiotic compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof. The compound of the present invention exhibits excellent antibacterial activity, especially against Gram bacteria. wherein each group is defined as in the description.

Compound acting as antibiotics

The present invention belongs to the field of pharmaceutical technology, and crystal forms of a 9-aminomethyl substituted tetracycline compound and a process for preparing the same. More specifically, the present invention relates to crystal forms of the compound represented by formula (1), a process for preparing crystal forms of the compound represented by formula (1) and use of said crystal forms in manufacture of medicament for treating and/or preventing an infection disease caused by tetracycline-sensitive bacteria and/or tetracycline-resistant bacteria. 

Crystal forms of a 9-aminomethyl substituted tetracycline compound and a preparation method thereof

The present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in reducing uric acid level, preventing or reducing inflammations, and preventing or treating uratic or gouty diseases. In particular, the present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in the manufacture of a medicament for the treatment or prevention of hyperuricemia, gout, gouty inflammations, pain and uric acid nephropathy. 

Prevention or treatment of uratic or gouty diseases

The invention relates to quinazoline derivatives substituted by aniline which are represented by the below formula (I), pharmaceutical acceptable salts and stereoisomer thereof, wherein these groups of R, R, R, R, R, R, L and n have the meanings given in the specification. The invention also relates to preparation methods, pharmaceutical compositions, pharmaceutical preparation and the use for preparation of medicine of treating excessive hyperplasia and chronic obstructive pulmonary disease and uses for treating excessive hyperplasia and chronic obstructive pulmonary disease thereof. 

Quinazoline derivatives substituted by aniline, preparation method and use thereof

The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y, Y, Y, R, R, R, R, R, R, Cy and n are as presented in the description. 

Fused ring compound for use as mineralocorticoid receptor antagonist

The present invention relates to benzimidazole derivatives and their pharmaceutical compositions and uses, specifically to benzimidazole derivatives of Formula (I), or their stereoisomer, pharmaceutically acceptable salt or solvates thereof, in which R, R, R, R, Rand n have the definitions in the description; the present invention further relates to a pharmaceutical composition containing the compounds, methods for preparing the compounds, and use of the compounds for manufacturing of a medicament for prophylaxis and/or treatment of peptic ulcer, ulcer hemorrhage and diseases associated with gastric acid. 

Benzimidazole derivatives and their pharmaceutical compositions and uses

The present invention relates to the crystalline form of carbapenems derivative or hydrate thereof and the preparation methods thereof. Specifically, the present invention relates to the crystalline form of carbapenem derivative (4R,5S,6S)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-3-(((3S,5S)-5-((4-sulfamoylbenzyl)carbamoyl)pyrrolidin-3-yl)thio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid as represented by formula (I) or hydrate thereof, characterized in that the X-ray powder diffraction pattern thereof using Cu-Ka radiation represented as 2&#x3b8; has characteristic peaks at 18.9&#xb1;0.2, 19.4&#xb1;0.2, 21.0&#xb1;0.2, 21.7&#xb1;0.2, and 23.4&#xb1;0.2, the preparation methods thereof, and the use thereof in the preparation of medicament for treating and/or preventing infectious diseases, as well as a pharmaceutical composition comprising such compound and one or more pharmaceutical carriers and/or diluents. 

Crystalline form of carbapenem derivative or its hydrates and preparation methods and uses thereof

Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R, R, R, Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the preparation methods, pharmaceutical compositions comprising the compounds and uses of the compounds in the manufacture of the medicine for the treatment and/or prevention of noninsulin-dependent diabetes, hyperglycemia, hyperlipidemia and insulin resistance. 

Fused pyridine derivatives

The present invention includes novel carbapenem derivatives having structural formula (I) or (II): wherein R, R, R, Rare described in the specification. The present invention also provides pharmaceutical compositions comprising the novel carbapenem derivatives and the use of the novel carbapenem derivatives for treating infectious diseases.

Carbapenem derivatives

The present invention relates to novel carbapenem derivatives and belongs to pharmaceutical field. Specifically, the present invention relates to the compounds as represented by formula (1), pharmaceutically acceptable salts, hydrolysable esters, isomers and intermediates thereof, wherein R, R, R, Rare described as in the description. The present invention also relates to the processes for the preparation of these compounds, to the pharmaceutical compositions comprising these compounds, and to their use for the manufacture of a medicament for the treatment and/or prevention of infectious diseases. 

Growing community of inventors

Jinan, China

Zhenhua Huang